Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121688713 | 12168871 | 3 | F | 20150313 | 20160721 | 20160310 | 20160729 | EXP | CA-PFIZER INC-2015097332 | PFIZER | 50.00 | YR | F | Y | 0.00000 | 20160729 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121688713 | 12168871 | 1 | PS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 121688713 | 12168871 | 2 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 121688713 | 12168871 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 15 MG, WEEKLY | 11719 | 15 | MG | /wk | |||||||
| 121688713 | 12168871 | 4 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 20 MG, WEEKLY | 11719 | 20 | MG | /wk | |||||||
| 121688713 | 12168871 | 5 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 12 MG, WEEKLY | 11719 | 12 | MG | /wk | |||||||
| 121688713 | 12168871 | 6 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 10 MG, WEEKLY | 11719 | 10 | MG | /wk | |||||||
| 121688713 | 12168871 | 7 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 25 MG, UNK | 11719 | 25 | MG | SOLUTION FOR INJECTION | |||||||
| 121688713 | 12168871 | 8 | C | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 200 MG, 2X/DAY | 0 | 200 | MG | TABLET | BID | |||||||
| 121688713 | 12168871 | 9 | C | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 200 MG, 1X/DAY | 0 | 200 | MG | TABLET | QD | |||||||
| 121688713 | 12168871 | 10 | C | FOLIC ACID. | FOLIC ACID | 1 | 5 MG, WEEKLY | 0 | 5 | MG | /wk | ||||||||
| 121688713 | 12168871 | 11 | C | NAPROSYN | NAPROXEN | 1 | 500 MG, 2X/DAY | 0 | 500 | MG | BID | ||||||||
| 121688713 | 12168871 | 12 | C | TYLENOL WITH CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | UNK, AS NEEDED | 0 | |||||||||||
| 121688713 | 12168871 | 13 | C | TYLENOL WITH CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | 0 | ||||||||||||
| 121688713 | 12168871 | 14 | C | VIMOVO | ESOMEPRAZOLE MAGNESIUMNAPROXEN | 1 | 500-20 MG, 2X/DAY | 0 | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 121688713 | 12168871 | 1 | Rheumatoid arthritis |
| 121688713 | 12168871 | 3 | Rheumatoid arthritis |
| 121688713 | 12168871 | 7 | Rheumatoid arthritis |
| 121688713 | 12168871 | 12 | Pain |
| 121688713 | 12168871 | 13 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 121688713 | 12168871 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 121688713 | 12168871 | Arthralgia | |
| 121688713 | 12168871 | Condition aggravated | |
| 121688713 | 12168871 | Lower respiratory tract infection | |
| 121688713 | 12168871 | Musculoskeletal pain | |
| 121688713 | 12168871 | Musculoskeletal stiffness | |
| 121688713 | 12168871 | Nasopharyngitis | |
| 121688713 | 12168871 | Sensitivity to weather change |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 121688713 | 12168871 | 1 | 20140927 | 0 | ||
| 121688713 | 12168871 | 2 | 201602 | 0 | ||
| 121688713 | 12168871 | 4 | 20140911 | 0 | ||
| 121688713 | 12168871 | 5 | 20150623 | 0 | ||
| 121688713 | 12168871 | 7 | 2014 | 0 |